Wedbush Expects Lower Earnings for Bicara Therapeutics

Key Points

• Wedbush analysts have lowered their Q3 2025 EPS estimate for Bicara Therapeutics from ($0.41) to ($0.46), while maintaining an "Outperform" rating and a $30 price target.
• The company reported a Q2 earnings of ($0.50) per share, which exceeded consensus estimates of ($0.54) by $0.04.
• Currently, Bicara Therapeutics has an average rating of "Moderate Buy" with a consensus target price of $31.86, amid mixed ratings from several analysts.

Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) - Investment analysts at Wedbush decreased their Q3 2025 earnings estimates for Bicara Therapeutics in a report issued on Tuesday, August 12th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of ($0.46) per share for the quarter, down from their previous estimate of ($0.41). Wedbush has a "Outperform" rating and a $30.00 price target on the stock. The consensus estimate for Bicara Therapeutics' current full-year earnings is ($2.59) per share. Wedbush also issued estimates for Bicara Therapeutics' Q4 2025 earnings at ($0.47) EPS, FY2025 earnings at ($2.11) EPS, Q1 2026 earnings at ($0.49) EPS, Q2 2026 earnings at ($0.50) EPS, Q3 2026 earnings at ($0.51) EPS, Q4 2026 earnings at ($0.52) EPS, FY2026 earnings at ($2.02) EPS, FY2027 earnings at ($2.25) EPS and FY2028 earnings at ($2.16) EPS.

Other research analysts have also issued reports about the stock. HC Wainwright dropped their price objective on shares of Bicara Therapeutics from $44.00 to $41.00 and set a "buy" rating for the company in a research note on Friday, May 16th. Piper Sandler began coverage on shares of Bicara Therapeutics in a research note on Monday. They set an "overweight" rating and a $36.00 price objective for the company. Wells Fargo & Company raised shares of Bicara Therapeutics from an "underweight" rating to an "equal weight" rating and set a $8.00 target price for the company in a research note on Friday, May 23rd. Finally, Wall Street Zen lowered shares of Bicara Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $32.38.

Bicara Therapeutics Stock Performance

NASDAQ BCAX traded down $0.4540 on Friday, hitting $11.0560. 365,267 shares of the stock were exchanged, compared to its average volume of 600,044. The stock has a fifty day moving average price of $10.41 and a two-hundred day moving average price of $11.93. The firm has a market capitalization of $603.25 million and a P/E ratio of -3.48. Bicara Therapeutics has a 52-week low of $7.80 and a 52-week high of $28.09.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.50) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.04.

Hedge Funds Weigh In On Bicara Therapeutics

A number of large investors have recently added to or reduced their stakes in BCAX. California State Teachers Retirement System bought a new position in Bicara Therapeutics in the fourth quarter worth about $25,000. CWM LLC bought a new position in Bicara Therapeutics in the first quarter worth about $29,000. Legal & General Group Plc raised its holdings in Bicara Therapeutics by 64.1% in the second quarter. Legal & General Group Plc now owns 3,156 shares of the company's stock worth $29,000 after purchasing an additional 1,233 shares in the last quarter. BNP Paribas Financial Markets bought a new position in Bicara Therapeutics in the fourth quarter worth about $32,000. Finally, Ameritas Investment Partners Inc. raised its holdings in Bicara Therapeutics by 73.0% in the second quarter. Ameritas Investment Partners Inc. now owns 3,493 shares of the company's stock worth $32,000 after purchasing an additional 1,474 shares in the last quarter.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.